{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:23:36Z","timestamp":1782743016269,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Over the years, reports have associated fluoroquinolones (FQ) with seizures. The incidence and whether FQ compared to non-epileptogenic antibiotic are associated with increased risk of seizures has yet to be examined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective observational study of hospitalized patients treated with FQ (ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin) or macrolides (MA: azithromycin or roxithromycin) between January 2009 and January 2021 in a large tertiary academic medical centre. The outcome was the occurrence of a seizure during treatment. The Naranjo scale was used to assess causality between FQ treatment and seizures. Comparative analysis was conducted using propensity score matching to correct for possible bias due to non-random selection, followed by inverse probability weighting (IPW) to estimate the difference in seizure risk between FQ and MA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 52\u200a722 patients were treated with FQ during a total of 178\u200a982 days. Mean age was 65 (\u00b119) years and 47% were females. Thirty-three patients (0.06%) experienced a seizure, yielding an incidence of 1:5422 treatment days. Causality was deemed probable and possible among 9\/33 and 24\/33, respectively. The MA group composed of 8522 patients treated during 17\u200a954 treatment days. Mean age was 65 (\u00b121) years, 49% were females. Six (0.07%) patients experienced each a single seizure. IPW estimated OR for seizures among the FQ versus MA group was 1.44 (95%CI 0.59\u20133.5, P\u200a=\u200a0.42).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The incidence of FQ associated seizures among hospitalized patients is low and the risk did not significantly exceed that under macrolides. Our results provide evidence for clinicians and decision-makers when balancing fluoroquinolones risks and benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae255","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T05:01:17Z","timestamp":1722574877000},"page":"2554-2560","source":"Crossref","is-referenced-by-count":8,"title":["Fluoroquinolones and the risk for incidental seizures: a comparative retrospective study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-8415","authenticated-orcid":false,"given":"Itai","family":"Gueta","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Internal Medicine A, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagith","family":"Yonath","sequence":"additional","affiliation":[{"name":"Internal Medicine A, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Danek Gertner Institute of Human Genetics, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Fluss","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Oberman","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oppenheim","sequence":"additional","affiliation":[{"name":"Internal Medicine A, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ozeri","sequence":"additional","affiliation":[{"name":"Internal Medicine A, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitshak","family":"Kreiss","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Biostatistics Unit, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Loebstein","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Sackler School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"2024093023505018700_dkae255-B1","author":"US Food and Drug Administrations"},{"key":"2024093023505018700_dkae255-B2","author":"US Food and Drug Administrations"},{"key":"2024093023505018700_dkae255-B3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.10359","article-title":"Seizures associated with fluoroquinolones","volume":"35","author":"Kushner","year":"2001","journal-title":"Ann Pharmacother"},{"key":"2024093023505018700_dkae255-B4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/01.jcp.0000162811.15066.8e","article-title":"Levofloxacin-related seizure activity in a patient with Alzheimer\u2019s disease: assessment of potential risk factors","volume":"25","author":"Bird","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"2024093023505018700_dkae255-B5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","article-title":"Quinlones: review of psychiatric and neurological adverse reactions","volume":"34","author":"Tom\u00e9","year":"2011","journal-title":"Drug Saf"},{"key":"2024093023505018700_dkae255-B6","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: a systematic review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology"},{"key":"2024093023505018700_dkae255-B7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jac\/31.4.457","article-title":"Antagonism of GABAA receptors by 4-quinolones","volume":"31","author":"Halliwell","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2024093023505018700_dkae255-B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/jac\/27.2.209","article-title":"The effects of quinolones and NSAIDs on GABA-evoked currents recorded from rat dorsal root ganglion neurons","volume":"27","author":"Halliwell","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2024093023505018700_dkae255-B9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1212\/WNL.0000000000002633","article-title":"Association between oral flouroquinolones and seizures: a self-controlled case series study","volume":"86","author":"Chui","year":"2016","journal-title":"Neurology"},{"key":"2024093023505018700_dkae255-B10","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/archneur.57.11.1617","article-title":"Seizures after stroke","volume":"57","author":"Bladin","year":"2000","journal-title":"Arch Neurol"},{"key":"2024093023505018700_dkae255-B11","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.arr.2021.101478","article-title":"Risk of seizures and subclinical epileptiform activity in patients with dementia: a systematic review and meta-analysis","volume":"72","author":"Zhao","year":"2021","journal-title":"Ageing Res Rev"},{"key":"2024093023505018700_dkae255-B12","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s10072-023-06695-y","article-title":"Frequency of seizures in patients with metastatic brain tumors","volume":"44","author":"Huntoon","year":"2023","journal-title":"Neurol Sci"},{"key":"2024093023505018700_dkae255-B13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/epi.17658","article-title":"Time-dependent risk factors for epileptic seizures in glioblastoma patients: a retrospective analysis of 520 cases","volume":"64","author":"Stritzelberger","year":"2023","journal-title":"Epilepsia"},{"key":"2024093023505018700_dkae255-B14","doi-asserted-by":"publisher","first-page":"109305","DOI":"10.1016\/j.drugalcdep.2022.109305","article-title":"Alcohol consumption on unprovoked seizure and epilepsy: an updated meta-analysis","volume":"232","author":"Woo","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2024093023505018700_dkae255-B15","author":"R Core Team"},{"key":"2024093023505018700_dkae255-B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"Suppl 2","key":"2024093023505018700_dkae255-B17","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024093023505018700_dkae255-B18","doi-asserted-by":"publisher","first-page":"a816","DOI":"10.1136\/bmj.a816","article-title":"FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"2024093023505018700_dkae255-B19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","article-title":"Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?","volume":"15","author":"Rusu","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024093023505018700_dkae255-B20","doi-asserted-by":"publisher","first-page":"e2136662","DOI":"10.1001\/jamanetworkopen.2021.36662","article-title":"Association of fluoroquinolones prescribing rates with black box warnings from the US food and drug administration","volume":"4","author":"Sankar","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024093023505018700_dkae255-B21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1017\/ice.2019.247","article-title":"Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals","volume":"40","author":"Yarrington","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024093023505018700_dkae255-B22","author":"European Medicines Agency"},{"key":"2024093023505018700_dkae255-B23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2024093023505018700_dkae255-B24","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/jgs.13039","article-title":"Levofloxacin and seizures: what risk for elderly adults?","volume":"62","author":"Famularo","year":"2014","journal-title":"J Am Geriatr Soc"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2554\/59459980\/dkae255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2554\/59459980\/dkae255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T23:50:58Z","timestamp":1727740258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/10\/2554\/7725806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,2]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae255","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,2]]}}}